Cargando…

Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells

Interleukin-10 (IL10) is best studied for its inhibitory action on immune cells and ability to suppress an antitumour immune response. But IL10 also exerts direct effects on nonimmune cells such as prostate cancer epithelial cells. Elevated serum levels of IL10 observed in prostate and other cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samiea, Abrar, Yoon, Jeff S. J., Ong, Christopher J., Zoubeidi, Amina, Chamberlain, Thomas C., Mui, Alice L.-F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415101/ https://www.ncbi.nlm.nih.gov/pubmed/32802517 http://dx.doi.org/10.1155/2020/5305306

Ejemplares similares

Interleukin-10 contributes to PGE(2) signalling through upregulation of EP4 via SHIP1 and STAT3
por: Samiea, Abrar, et al.
Publicado: (2020)

Interleukin-10 and Small Molecule SHIP1 Allosteric Regulators Trigger Anti-inflammatory Effects through SHIP1/STAT3 Complexes
por: Chamberlain, Thomas C., et al.
Publicado: (2020)

Interleukin-10 control of pre-miR155 maturation involves CELF2
por: Yoon, Jeff S. J., et al.
Publicado: (2020)

Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L, et al.
Publicado: (2013)

Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action?
por: Islam, Hashim, et al.
Publicado: (2021)

Co‐targeting driver pathways in prostate cancer: two birds with one stone
por: Zoubeidi, Amina, et al.
Publicado: (2018)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells
por: Davies, Alastair H., et al.
Publicado: (2016)

The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
por: Bishop, Jennifer L., et al.
Publicado: (2014)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
por: Toren, Paul, et al.
Publicado: (2016)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Interleukin-10 Inhibits Lipopolysaccharide Induced miR-155 Precursor Stability and Maturation
por: Cheung, Sylvia T., et al.
Publicado: (2013)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Hyporesponsiveness to the anti-inflammatory action of interleukin-10 in type 2 diabetes
por: Barry, Julianne C., et al.
Publicado: (2016)

Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models
por: Sooreshjani, Moloud Aflaki, et al.
Publicado: (2021)

VISTA, PDL-L1, and BRAF—A Review of New and Old Markers in the Prognosis of Melanoma
por: Tinca, Andreea Cătălina, et al.
Publicado: (2022)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer
por: Luo, Bixian, et al.
Publicado: (2022)

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
por: Ramnarine, Varune Rohan, et al.
Publicado: (2018)

ONECUT2 is a driver of neuroendocrine prostate cancer
por: Guo, Haiyang, et al.
Publicado: (2019)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
por: Hsu, En-Chi, et al.
Publicado: (2020)

Anion binding properties of a hollow PdL-cage
por: Timmer, Brian J. J., et al.
Publicado: (2021)

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
por: Sama, Shashank, et al.
Publicado: (2019)

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L., et al.
Publicado: (2014)

PDL1 expression on monocytes is associated with plasma cytokines in Tuberculosis and HIV
por: Tamene, Wegene, et al.
Publicado: (2021)

Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia
por: Melong, Nicole, et al.
Publicado: (2017)

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer
por: Singh, Neha, et al.
Publicado: (2021)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
por: Baca, Sylvan C., et al.
Publicado: (2021)

Effects of treatment with local anesthetics on RANKL expression in MG63 and PDL cells
por: Huang, Tsui-Hsein, et al.
Publicado: (2021)

Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
por: Chen, Yundi, et al.
Publicado: (2021)

Role of PDL1 as a prognostic marker in renal cell carcinoma: a prospective observational study in eastern India
por: Kumar, Barun, et al.
Publicado: (2019)

Stimulation of MMP-1 and CCL2 by NAMPT in PDL Cells
por: Nokhbehsaim, Marjan, et al.
Publicado: (2013)

Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells
por: Jain, Pallavi, et al.
Publicado: (2019)

PDL1 Regulation by p53 via miR-34
por: Cortez, Maria Angelica, et al.
Publicado: (2015)

Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer
por: Ma, Yun-Feng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3g97ql34p090m23a87u1v6ql4k